Ionis Pharmaceuticals (IONS) to Release Quarterly Earnings on Wednesday

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Wednesday, July 30th. Analysts expect Ionis Pharmaceuticals to post earnings of $0.19 per share and revenue of $270.90 million for the quarter. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported ($0.93) EPS for the quarter, beating analysts' consensus estimates of ($1.07) by $0.14. Ionis Pharmaceuticals had a negative return on equity of 91.85% and a negative net margin of 63.65%. The business had revenue of $132.00 million for the quarter, compared to analyst estimates of $144.31 million. During the same quarter in the prior year, the firm posted ($0.98) EPS. The firm's revenue for the quarter was up 10.9% on a year-over-year basis. On average, analysts expect Ionis Pharmaceuticals to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Ionis Pharmaceuticals Stock Performance

NASDAQ:IONS traded up $0.09 during mid-day trading on Friday, hitting $42.24. 887,852 shares of the company's stock traded hands, compared to its average volume of 1,810,999. The firm has a 50 day moving average of $38.20 and a two-hundred day moving average of $33.83. The company has a current ratio of 9.66, a quick ratio of 9.62 and a debt-to-equity ratio of 2.63. Ionis Pharmaceuticals has a 12 month low of $23.95 and a 12 month high of $52.34. The firm has a market capitalization of $6.72 billion, a price-to-earnings ratio of -14.13 and a beta of 0.23.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on IONS shares. Guggenheim dropped their price target on Ionis Pharmaceuticals from $65.00 to $64.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Needham & Company LLC reduced their price target on Ionis Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Ionis Pharmaceuticals in a research report on Thursday, June 26th. Redburn Atlantic began coverage on Ionis Pharmaceuticals in a report on Monday, March 31st. They set a "neutral" rating and a $39.00 target price on the stock. Finally, JPMorgan Chase & Co. lifted their price target on Ionis Pharmaceuticals from $45.00 to $48.00 and gave the company a "neutral" rating in a research note on Thursday, June 12th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $55.67.

Insiders Place Their Bets

In other Ionis Pharmaceuticals news, Director Michael R. Hayden purchased 15,000 shares of the stock in a transaction on Thursday, May 1st. The stock was acquired at an average cost of $31.86 per share, with a total value of $477,900.00. Following the completion of the purchase, the director directly owned 50,219 shares of the company's stock, valued at approximately $1,599,977.34. This trade represents a 42.59% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Brett P. Monia sold 1,160 shares of the company's stock in a transaction dated Friday, July 11th. The shares were sold at an average price of $41.74, for a total transaction of $48,418.40. Following the transaction, the chief executive officer directly owned 179,820 shares of the company's stock, valued at approximately $7,505,686.80. This trade represents a 0.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Ionis Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Focus Partners Wealth grew its holdings in shares of Ionis Pharmaceuticals by 30.1% during the first quarter. Focus Partners Wealth now owns 9,832 shares of the company's stock valued at $297,000 after buying an additional 2,277 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Ionis Pharmaceuticals by 6.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 659,435 shares of the company's stock worth $19,895,000 after acquiring an additional 39,794 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Ionis Pharmaceuticals by 72.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 652,518 shares of the company's stock worth $19,686,000 after acquiring an additional 274,310 shares during the last quarter. 93.86% of the stock is owned by institutional investors.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.